Skip to main content

Hepatitis Viruses: Hepatitis B and Hepatitis D

  • Chapter
  • First Online:
Viral Infections of Humans

Abstract

Infection with hepatitis B virus (HBV) is the most common cause of chronic hepatitis and hepatocellular carcinoma in the world today despite the availability of an effective vaccine and antiviral therapies for some patients. The virus causes both acute and chronic infections. It is estimated that at least 350 million in the world today are chronically infected with HBV. The epidemiology of this viral infection has revealed effective strategies for prevention and control that may lead to future reductions in the burden of disease. Hepatitis D virus, also known as delta virus, is a defective virus that cannot establish or maintain infection except in the presence of HBV. While the global impact of HDV infection is less than that of HBV alone, its prevention and control represent unique challenges due to its unusual characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. WHO. Hepatitis B (WHO/CDS/CSR/LYO/2002.2: hepatitis B). 2002. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index.html. Accessed 15 Dec 2012.

  2. Belongia EA, Costa J, Gareen IF, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements. 2008;25:1–29.

    PubMed  CAS  Google Scholar 

  3. Cohen C, Holmberg SD, McMahon BJ, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat. 2011;18:377–83.

    PubMed  CAS  Google Scholar 

  4. Blumberg BS. Hepatitis B: the hunt for a killer virus. Princeton: Princeton University Press; 2002.

    Google Scholar 

  5. Krugman S. Viral hepatitis: overview and historical perspectives. Yale J Biol Med. 1976;49:199–203.

    PubMed  CAS  PubMed Central  Google Scholar 

  6. Freeman G. Epidemiology and incubation period of jaundice following yellow fever vaccination. Am J Trop Med Hyg. 1946;26:15–32.

    PubMed  CAS  Google Scholar 

  7. Blumberg BS, Alter HJ, Visnich S. A “New” antigen in leukemia sera. JAMA. 1965;191:541–6.

    PubMed  CAS  Google Scholar 

  8. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66:924–31.

    PubMed  CAS  Google Scholar 

  9. London WT, Blumberg BS. Comments on the role of epidemiology in the investigation of hepatitis B virus. Epidemiol Rev. 1985;7:59–79.

    PubMed  CAS  Google Scholar 

  10. Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s syndrome and hepatitis. Nature. 1968;218:1057–9.

    PubMed  CAS  Google Scholar 

  11. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970;1:695–8.

    PubMed  CAS  Google Scholar 

  12. Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A. 1968;60:814–21.

    PubMed  CAS  PubMed Central  Google Scholar 

  13. Lustbader ED, London WT, Blumberg BS. Study design for a hepatitis B vaccine trial. Proc Natl Acad Sci. 1976;73:955–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  14. Beasley RP. Hepatitis B, virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942–56.

    PubMed  CAS  Google Scholar 

  15. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129–33.

    PubMed  CAS  Google Scholar 

  16. Organization WH, Hepatitis B. Factsheet no. 204. 2012. Geneva: World Health Organization; 2012.

    Google Scholar 

  17. The ABCs of hepatitis fact sheet. 2012. http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable.pdf. Accessed 1 Dec 2012.

  18. Viral Hepatitis Surveillance – United States, 2010. 2012. http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/PDFs/2010HepSurveillanceRpt.pdf. Accessed 1 Dec 2012.

  19. Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP. Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology. 2008;47:1150–7.

    PubMed  Google Scholar 

  20. Finelli L, Bell BP. Chapter 4: Hepatitis B. In: Roush SW, McIntyre L, Baldy LM, editors. Manual for the surveillance of vaccine-preventable diseases. 5th ed. Atlanta: Centers for Disease Control and Prevention; 2011.

    Google Scholar 

  21. James L, Fong C, Foong B, et al. Hepatitis B seroprevalence study 1999. Singapore Med J. 2001;42:420–4.

    PubMed  CAS  Google Scholar 

  22. Chen C-H, Yang P-M, Huang G-T, Lee H-S, Sung J-L, Sheu J-C. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106:148–55.

    PubMed  Google Scholar 

  23. Martinson FE, Weigle KA, Mushahwar IK, Weber DJ, Royce R, Lemon SM. Seroepidemiological survey of hepatitis B and C virus infections in Ghanaian children. J Med Virol. 1998;48:278–83.

    Google Scholar 

  24. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

    PubMed  CAS  Google Scholar 

  25. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–7.

    PubMed  Google Scholar 

  26. Cohen C, Evans AA, London WT, Block J, Conti M, Block T. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 2008;15:12–3.

    PubMed  CAS  PubMed Central  Google Scholar 

  27. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin. Hepatology. 2012;56(2):422–33.

    PubMed  Google Scholar 

  28. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.

    PubMed  CAS  Google Scholar 

  29. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64:51–68.

    PubMed  CAS  PubMed Central  Google Scholar 

  30. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology. 2011;53:2121–9.

    PubMed  CAS  Google Scholar 

  31. CDC. Epidemiology and prevention of vaccine-preventable diseases. 12th ed, 2nd printing ed. Washington, DC: Public Health Foundation; 2012. p. 115–38.

    Google Scholar 

  32. Hoofnagle J. Serologic markers of hepatitis B virus infection. Annu Rev Med. 1981;32:1–11.

    PubMed  CAS  Google Scholar 

  33. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol. 2013;35:39–52.

    PubMed  CAS  PubMed Central  Google Scholar 

  34. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231–40.

    PubMed  Google Scholar 

  35. Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45:238–44.

    PubMed  Google Scholar 

  36. Gerlich WH. The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg. Clin Infect Dis. 2007;44:1170–2.

    PubMed  CAS  Google Scholar 

  37. CDC. Guidelines for viral hepatitis surveillance and case management. Atlanta: Centers for Disease Control and Prevention, Division of Viral Hepatitis; 2005.

    Google Scholar 

  38. Smith HM, Lau JYN, Davies SE, Daniels HM, Alexander GJM, Williams R. Significance of serum IgM anti‐HBc in chronic hepatitis B virus infection. J Med Virol. 1992;36:16–20.

    PubMed  CAS  Google Scholar 

  39. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the “healthy” HBsAg carrier state. Hepatology. 1987;7:758–63.

    PubMed  CAS  Google Scholar 

  40. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759–68.

    PubMed  CAS  Google Scholar 

  41. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–55.

    PubMed  CAS  Google Scholar 

  42. Vivekanandan P, Singh OV. Molecular methods in the diagnosis and management of chronic hepatitis B. Expert Rev Mol Diagn. 2010;10:921–35.

    PubMed  CAS  Google Scholar 

  43. Prince AM, Lee DH, Brotman B. Infectivity of blood from PCR‐positive, HBsAg‐negative, anti‐HBs‐positive cases of resolved hepatitis B infection. Transfusion (Paris). 2002;41:329–32.

    Google Scholar 

  44. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis. 2004;24:3–10.

    PubMed  CAS  Google Scholar 

  45. Brooks GF, Butel JS, Morse SA. Jawetz, Melnick, & Adelberg’s medical microbiology. New York: McGraw-Hill Medical; 2007.

    Google Scholar 

  46. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci. 1996;93:4398–402.

    PubMed  CAS  PubMed Central  Google Scholar 

  47. Chu CJ, Lok ASF. Clinical significance of hepatitis B virus genotypes. Hepatology. 2003;35:1274–6.

    Google Scholar 

  48. Carman WF, Karayiannis P, Waters J, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325–9.

    PubMed  CAS  Google Scholar 

  49. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol. 2011;26 Suppl 1:123–30.

    PubMed  Google Scholar 

  50. Kao JH. Hepatitis B, viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17:643–50.

    PubMed  CAS  Google Scholar 

  51. Kobayashi H, Tsuzuki M, Koshimizu K, et al. Susceptibility of hepatitis B virus to disinfectants or heat. J Clin Microbiol. 1984;20:214–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  52. Soběslavský O. Prevalence of markers of hepatitis B virus infection in various countries: a WHO collaborative study. Bull World Health Organ. 1980;58:621.

    PubMed  PubMed Central  Google Scholar 

  53. WHO. Introduction of hepatitis B vaccine into childhood immunization services: management guidelines, including information for health workers and parents. Geneva: World Health Organization; 2001.

    Google Scholar 

  54. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003;39:64–9.

    Google Scholar 

  55. CDC. Healthcare-Associated Hepatitis B and C Outbreaks Reported to the Centers for Disease Control and Prevention (CDC) in 2008–2011. CDC, 2012. http://www.cdc.gov/hepatitis/statistics/healthcareoutbreaktable.htm.

  56. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med. 2009;150:33.

    PubMed  Google Scholar 

  57. Teo C. Molecular epidemiology of hepatitis B in England and Wales. J Clin Virol. 2005;34:S13–4.

    PubMed  CAS  Google Scholar 

  58. Andersson MI, Low N, Irish CJ, et al. Molecular epidemiology of a large community-based outbreak of hepatitis B in Bristol, UK. J Clin Virol. 2012;53:125–9.

    PubMed  Google Scholar 

  59. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005. New York: Thieme-Stratton, c1981-. p. 3–8.

    Google Scholar 

  60. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603.

    PubMed  CAS  Google Scholar 

  61. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–25.

    PubMed  Google Scholar 

  62. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992–1000.

    PubMed  CAS  Google Scholar 

  63. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55:1–33; quiz CE1–4.

    PubMed  Google Scholar 

  64. Woodruff BA, Moyer LA, O’Rourke KM, Margolis HS. Blood exposure and the risk of hepatitis B virus infection in firefighters. J Occup Med. 1993;35:1048–54.

    PubMed  CAS  Google Scholar 

  65. Turner SB, Kunches LM, Gordon KF, Travers PH, Mueller NE. Occupational exposure to human immunodeficiency virus (HIV) and hepatitis B virus (HBV) among embalmers: a pilot seroprevalence study. Am J Public Health. 1989;79:1425–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  66. Lehman EJ, Huy J, Levy E, Viet SM, Mobley A, McCleery TZ. Bloodborne pathogen risk reduction activities in the body piercing and tattooing industry. Am J Infect Control. 2010;38:130–8.

    PubMed  Google Scholar 

  67. Heymann DL, American Public Health Association. Control of communicable diseases manual. Washington, DC: American Public Health Association; 2004.

    Google Scholar 

  68. Chen X, Chen J, Wen J, et al. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus. PLoS One. 2013;8:e55303.

    PubMed  CAS  PubMed Central  Google Scholar 

  69. Breastfeeding: diseases and conditions: hepatitis B and C infections. 2009. http://www.cdc.gov/breastfeeding/disease/hepatitis.htm. Accessed 1 Feb 2012.

  70. Heiberg IL, Hogh B. Horizontal transmission of hepatitis B virus—why discuss when we can vaccinate? J Infect Dis. 2012;206:464–5.

    Google Scholar 

  71. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–4.

    PubMed  CAS  Google Scholar 

  72. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol. 1979;3:237–41.

    PubMed  CAS  Google Scholar 

  73. Shao ZJ, Zhang L, Xu JQ, et al. Mother‐to‐infant transmission of hepatitis B virus: a Chinese experience. J Med Virol. 2011;83:791–5.

    PubMed  Google Scholar 

  74. Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007;12:160–7. Elsevier.

    PubMed  Google Scholar 

  75. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine. 1999;17:1730–3.

    PubMed  CAS  Google Scholar 

  76. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS. 2004;15:7–16.

    PubMed  Google Scholar 

  77. CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1–42.

    Google Scholar 

  78. Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546–50.

    PubMed  Google Scholar 

  79. Holmberg SD, Suryaprasad A, Ward JW. Updated CDC recommendations for the management of hepatitis B virus–infected health-care providers and students. MMWR Recomm Rep. 2012;16:1–10.

    Google Scholar 

  80. Khan AJ, Simard EP, Bower WA, et al. Ongoing transmission of hepatitis B virus infection among inmates at a state correctional facility. Am J Public Health. 2005;95:1793–9.

    PubMed  PubMed Central  Google Scholar 

  81. Samuel M, Doherty P, Bulterys M, Jenison S. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2001;127:475–84.

    PubMed  CAS  PubMed Central  Google Scholar 

  82. Nishioka SA, Gyorkos TW. Tattoos as risk factors for transfusion-transmitted diseases. Int J Infect Dis. 2001;5:27–34.

    PubMed  Google Scholar 

  83. Petersen NJ, Barrett DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol. 1976;32:572–4.

    PubMed  CAS  PubMed Central  Google Scholar 

  84. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Sem Liver Dis. 1991;11:84–92.

    CAS  Google Scholar 

  85. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics. 1992;89:269–73.

    PubMed  CAS  Google Scholar 

  86. McQuillan G, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999;89:14–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  87. Brook M. Sexually acquired hepatitis. Sex Transm Infect. 2002;78:235–40.

    PubMed  CAS  PubMed Central  Google Scholar 

  88. Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis. 2004;8:403–18.

    PubMed  Google Scholar 

  89. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun. 2001;16:269–74.

    PubMed  CAS  Google Scholar 

  90. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis. 2006;1:23–61.

    CAS  Google Scholar 

  91. Inoue J. Factors involved in the development of fulminant hepatitis B: are the mutations of hepatitis B virus implicated? Hepatol Res. 2009;39:1053–5.

    PubMed  CAS  Google Scholar 

  92. Lok AS. Hepatitis B, infection: pathogenesis and management. J Hepatol. 2000;32:89–97.

    PubMed  CAS  Google Scholar 

  93. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis. 1999;19:157–69.

    PubMed  CAS  Google Scholar 

  94. Belongia EA, Costa J, Gareen IF et al. NIH consensus development conference statement on management of hepatitis B. Ann Intern Med. 2009;150:104–10.

    PubMed  Google Scholar 

  95. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase. Hepatology. 2007;46:395–401.

    PubMed  Google Scholar 

  96. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839–43.

    PubMed  CAS  Google Scholar 

  97. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.

    PubMed  Google Scholar 

  98. Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. J Infect Dis. 1997;176:845–50.

    PubMed  CAS  Google Scholar 

  99. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051–4.

    PubMed  CAS  Google Scholar 

  100. Chen C, Yang H, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.

    PubMed  CAS  Google Scholar 

  101. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797–803.

    PubMed  Google Scholar 

  102. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28:2437–44.

    PubMed  Google Scholar 

  103. Harris RA, Chen G, Lin W-Y, Shen FM, London WT, Evans AA. Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population. Cancer Causes Control. 2003;14:995–1000.

    PubMed  Google Scholar 

  104. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008;15:137–45.

    PubMed  Google Scholar 

  105. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int. 2009;3:334–42.

    PubMed  PubMed Central  Google Scholar 

  106. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol. 2004;72:363–9.

    PubMed  CAS  Google Scholar 

  107. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133:1452–7.

    PubMed  CAS  Google Scholar 

  108. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans. J Med Virol. 2005;75:513–21.

    PubMed  CAS  Google Scholar 

  109. Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat. 2010;17:601–10.

    PubMed  CAS  Google Scholar 

  110. Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis. 2012;16:347–69.

    PubMed  Google Scholar 

  111. Blumberg BS. Hepatitis B, virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci. 1997;94:7121–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  112. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833–41.

    PubMed  CAS  Google Scholar 

  113. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348–55.

    PubMed  CAS  Google Scholar 

  114. WHO. Global routine vaccination coverage, 2011. Wkly Epidemiol Rec. 2012;87:432.

    Google Scholar 

  115. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329–39.

    PubMed  Google Scholar 

  116. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650–5.

    PubMed  Google Scholar 

  117. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54:1–31.

    PubMed  Google Scholar 

  118. Lin Y-C, Chang M-H, Ni Y-H, Hsu H-Y, Chen D-S. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003;187:134–8.

    PubMed  Google Scholar 

  119. Beasley RP, Hwang LY, Lin CC, et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet. 1981;2:388–93.

    PubMed  CAS  Google Scholar 

  120. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257:2612–6.

    PubMed  CAS  Google Scholar 

  121. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54:1–31.

    Google Scholar 

  122. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national perinatal hepatitis B prevention program, 1994–2008. Pediatrics. 2012;129:609–16.

    PubMed  Google Scholar 

  123. HBF Drug Watch. 2012. http://www.hepb.org/professionals/hbf_drug_watch.htm. Accessed 15 Dec 2012.

  124. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.

    PubMed  CAS  Google Scholar 

  125. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

    PubMed  Google Scholar 

  126. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–41.

    PubMed  CAS  Google Scholar 

  127. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–62.

    PubMed  CAS  Google Scholar 

  128. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.

    Google Scholar 

  129. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–83.

    PubMed  PubMed Central  Google Scholar 

  130. Tong MJ, Pan CQ, Hann HW, et al. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011;56:3143–62.

    PubMed  CAS  Google Scholar 

  131. Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update. J Gastroenterol Hepatol. 2011;26:829–35.

    PubMed  CAS  Google Scholar 

  132. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348–56.

    PubMed  CAS  Google Scholar 

  133. Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol. 2011;26:221–7.

    PubMed  Google Scholar 

  134. Hosaka T, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatol. 2013;58(1):98–107.

    Google Scholar 

  135. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. 2006;13:787–98.

    PubMed  CAS  Google Scholar 

  136. Evans AA, London WT, Gish RG, Cohen C, Block TM. Chronic HBV infection outside treatment guidelines: is treatment needed? Antivir Ther. 2012;18(2):229–35.

    PubMed  Google Scholar 

  137. WHO. Hepatitis B fact sheet no. 204. Geneva: World Health Organization; 2012.

    Google Scholar 

  138. Hoofnagle JH. Action plan for liver disease research. Hepatology. 2004;40:1240.

    Google Scholar 

  139. Block TM, Gish R, Guo H, et al. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 2013;98:27–34.

    PubMed  CAS  PubMed Central  Google Scholar 

  140. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293–1302.e4.

    PubMed  Google Scholar 

  141. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol. 2010;25:19–25.

    PubMed  Google Scholar 

  142. Rizzetto M, Canese M, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997–1003.

    PubMed  CAS  PubMed Central  Google Scholar 

  143. Bonino F, Hoyer B, Shih J, Rizzetto M, Purcell R, Gerin J. Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun. 1984;43:1000–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  144. Canese MG, Rizzetto M, Novara R, London WT, Purcell RH. Experimental infection of chimpanzees with the HBsAg‐associated delta (δdL) agent: an ultrastructural study. J Med Virol. 1984;13:63–72.

    PubMed  CAS  Google Scholar 

  145. Rizzetto M, Canese MG, Purcell RH, London WT, David Sly L, Gerin JL. Experimental HBV and δ infections of chimpanzees: occurrence and significance of intrahepatic immune complexes of HBcAg and δ antigen. Hepatology. 1981;1:567–74.

    PubMed  CAS  Google Scholar 

  146. Taylor JM. The structure and replication of hepatitis delta virus. Annu Rev Microbiol. 1992;46:253–76.

    PubMed  CAS  Google Scholar 

  147. Taylor JM. Hepatitis delta virus: cis and trans functions required for replication. Cell. 1990;61:371–3.

    PubMed  CAS  Google Scholar 

  148. Taylor JM. Replication of human hepatitis delta virus: influence of studies on subviral plant pathogens. Adv Virus Res. 1999;54:45–60.

    PubMed  CAS  Google Scholar 

  149. Farci P. Delta hepatitis: an update. J Hepatol. 2003;39 Suppl 1:S212–9.

    PubMed  CAS  Google Scholar 

  150. FitzSimons D, François G, Bonanni P, et al. Prevention of viral hepatitis in Italy. Vaccine. 2004;22:4092–6.

    PubMed  Google Scholar 

  151. Viral Hepatitis Prevention Board. Prevention and control of viral hepatitis in Greece: lessons learnt and the way forward. Viral Hepatitis Prevention Board. Athens; 2008;16:1–28.

    Google Scholar 

  152. Blue Book: guidelines for control of infectious diseases. 2007. http://ideas.health.vic.gov.au/bluebook/hepatitis-d.asp. Accessed 5 Mar 2013.

  153. Department of Health and Ageing AG. Australia’s notifiable diseases status, 2010: Annual report of the National Notifiable Diseases Surveillance System – Results: Bloodborne diseases. Commun Dis Intell. 2012;36:83–4.

    Google Scholar 

  154. Guidelines For viral hepatitis surveillance and case management. 2008. http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm. Accessed Mar 1 2013.

  155. Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008;80:277–82.

    PubMed  Google Scholar 

  156. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211–9.

    PubMed  Google Scholar 

  157. Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res. 1991;364:1–20.

    PubMed  CAS  Google Scholar 

  158. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40.

    PubMed  Google Scholar 

  159. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.

    PubMed  Google Scholar 

  160. Gaeta GB, Stroffolini T, Smedile A, Niro G, Mele A. Hepatitis delta in Europe: vanishing or refreshing? Hepatology. 2007;46:1312–3.

    PubMed  Google Scholar 

  161. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection—not a vanishing disease in Europe! Hepatology. 2007;45:1331–2.

    PubMed  Google Scholar 

  162. Huo TI, Wu JC, Wu SI, et al. Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. J Med Virol. 2004;72:41–5.

    PubMed  Google Scholar 

  163. Wedemeyer H. Hepatitis D, revival. Liver Int. 2011;31:140–4.

    PubMed  Google Scholar 

  164. Salassa B, Daziano E, Bonino F, et al. Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection. J Hepatol. 1991;12:10–3.

    PubMed  CAS  Google Scholar 

  165. Perillo R. Hepatitis B, and D. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease-2 volume set: pathophysiology, diagnosis, management, expert consult. Philadelphia: Saunders Elsevier; 2010. p. 1287–312.

    Google Scholar 

  166. Yang G, Vyas GN. Immunodiagnosis of viral hepatitides A to E and non-A to -E. Clin Diagn Lab Immunol. 1996;3:247–56.

    PubMed  CAS  PubMed Central  Google Scholar 

  167. Harrison PM, Lau JY, Williams R. Hepatology. Postgrad Med J. 1991;67:719–41.

    PubMed  CAS  PubMed Central  Google Scholar 

  168. WHO. Hepatitis delta WHO/CDS/CSR/NCS/2001.1 2001. http://www.who.int/csr/disease/hepatitis/whocdscsrncs20011/en/index.html. Accessed 1 Mar 2013.

  169. Casey JL. Hepatitis delta virus. Genetics and pathogenesis. Clin Lab Med. 1996;16:451–64.

    PubMed  CAS  Google Scholar 

  170. Le Gal F, Gault E, Ripault MP, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis. 2006;12:1447–50.

    PubMed  PubMed Central  Google Scholar 

  171. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int. 2011;31:7–21.

    PubMed  CAS  Google Scholar 

  172. Makuwa M, Caron M, Souquière S, Malonga-Mouelet G, Mahé A, Kazanji M. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol. 2008;46:754–6.

    PubMed  PubMed Central  Google Scholar 

  173. Lok AS, Wong A, Sporton S, Lai CL, Liu V, Chung HT. Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. J Hepatol. 1992;14:332–4.

    PubMed  CAS  Google Scholar 

  174. Abbas Z, Jafri W, Raza S. Hepatitis D: scenario in the Asia-Pacific region. World J Gastroenterol. 2010;16:554–62.

    PubMed  PubMed Central  Google Scholar 

  175. Flodgren E, Bengtsson S, Knutsson M, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol. 2000;38:3311–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  176. Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio PL. Italian Hospitals’ Collaborating G. Chronic hepatitis B in Italy: new features of an old disease–approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008;46:110–3.

    PubMed  Google Scholar 

  177. Sagnelli E, Stroffolini T, Ascione A, et al. The epidemiology of hepatitis delta infection in Italy. Promoting Group. J Hepatol. 1992;15:211–5.

    PubMed  CAS  Google Scholar 

  178. Mele A, Mariano A, Tosti ME, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis. 2007;44:e17–24.

    PubMed  Google Scholar 

  179. Alavian S-M. Hepatitis D is a forgotten problem in hemodialysis patients in the world. Hepat Mon. 2008;8:1.

    Google Scholar 

  180. Niro GA, Casey JL, Gravinese E, et al. Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol. 1999;30:564–9.

    PubMed  CAS  Google Scholar 

  181. Arico S, Aragona M, Rizzetto M, et al. Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. Lancet. 1985;2:356–8.

    PubMed  CAS  Google Scholar 

  182. Guilhot S, Huang S, Xia YP, La Monica N, Lai M, Chisari FV. Expression of the hepatitis delta virus large and small antigens in transgenic mice. J Virol. 1994;68:1052–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  183. Taylor JM. Hepatitis delta virus. Virology. 2006;344:71–6.

    PubMed  CAS  Google Scholar 

  184. IARC. Monographs on the evaluation of carcinogenic risk to humans. IARC Monographs. 1994;59:45–221.

    Google Scholar 

  185. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000;46:420–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  186. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:790–2.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alison A. Evans ScD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Evans, A.A., Cohen, C., Block, T.M. (2014). Hepatitis Viruses: Hepatitis B and Hepatitis D . In: Kaslow, R., Stanberry, L., Le Duc, J. (eds) Viral Infections of Humans. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7448-8_32

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-7448-8_32

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-7447-1

  • Online ISBN: 978-1-4899-7448-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics